Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Voyager Therapeutics (VYGR – Research Report). The associated price target is $10.00.
Yanan Zhu has given his Buy rating due to a combination of factors related to Voyager Therapeutics’ promising developments in Alzheimer’s disease treatments. The company presented encouraging preclinical data for its VY7523 and VY1706 programs at the AD/PD conference, showcasing significant reductions in tau spread in mouse models. These results suggest potential efficacy in targeting tau pathology, a key aspect of Alzheimer’s disease progression.
Moreover, Voyager Therapeutics’ VY1706 program demonstrated substantial tau mRNA reductions in non-human primates, indicating promising gene therapy potential. The company also addressed concerns about observed side effects, noting that they were expected and resolved over time. With ongoing studies and data expected in the coming years, Voyager’s advancements in tau-targeting therapies provide a strong basis for optimism, supporting the Buy rating.
Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Sangamo Biosciences, and uniQure. According to TipRanks, Zhu has an average return of -14.9% and a 20.56% success rate on recommended stocks.